Where does CERO stock trade?

CERo Therapeutics Holdings Inc. (CERO) is listed on NASDAQ.

What sector and industry is CERO in?

CERo Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.

When did CERo Therapeutics Holdings Inc. go public?

CERo Therapeutics Holdings Inc. (CERO) completed its IPO in 2021.

What are analysts saying about CERO?

CERo Therapeutics Holdings Inc. has had 1 recent analyst action on file. The most recent action was from D. Boral Capital: Buy with a $3000.00 price target on 2025-06-23. Recent price targets cluster around $3000.00.

What companies are similar to CERO?

Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CERO side-by-side with any of them on Quantisnow.

How can I track CERO on Quantisnow?

Quantisnow aggregates CERo Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERO to receive live email and push alerts on every new disclosure.

CERO

NASDAQ

CERo Therapeutics Holdings Inc.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2021

$0.10-1.66 (-94.51%)

News25/Ratings1

Price$0.10+0.00 (+0.00%)

2026-02-272026-06-02

News · 26 weeks42-55%

2025-12-072026-05-31

Mix1990d

SEC Filings12(63%)
Other4(21%)
Insider2(11%)
Leadership1(5%)

Latest news

25 items

4dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
4dSEC
CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
18dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
18dSEC
SEC Form 10-Q filed by CERo Therapeutics Holdings Inc.
10-Q - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
23dPR
CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing next-generation engineered T cell therapeutics that employ phagocytic mechanisms, announces that it has completed dosing and the 28-day dose-limiting toxicity ("DLT") assessment period for all three patients in the second cohort of its Phase 1 CERTAIN-T clinical trial of CER-1236 in hematologic malignancies. In the second cohort, patients received CER-1236 at a total dose o
32dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
32dSEC
CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
32dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
33dSEC
Amendment: SEC Form 10-K/A filed by CERo Therapeutics Holdings Inc.
10-K/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
42dINSIDER
SEC Form 4 filed by Francois Eric
4 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
42dINSIDER
SEC Form 3 filed by new insider Francois Eric
3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)
48dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
48dSEC
SEC Form 10-K filed by CERo Therapeutics Holdings Inc.
10-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
49dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
49dSEC
CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
50dPR
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
Study will advance into expanded patient populations with myelodysplastic syndrome (MDS) and myelofibrosis (MF) SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the third patient in the second cohort (sixth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies. The patient had MDS that evolved to acute myeloid leukemia (AML). The trial was recently expanded to include earlier forms of MDS and myelof
62dSEC
SEC Form NT 10-K filed by CERo Therapeutics Holdings Inc.
NT 10-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
65dPR
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
Trial advancing with ongoing safety and pharmacologic evaluation and planned expansion into MDS and MF SOUTH SAN FRANCISCO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company") an innovative cellular immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces it has dosed the second patient in the second cohort (fifth patient overall) in its Phase 1 CER-1236 clinical trial in hematologic malignancies, including acute myeloid leukemia (AML), with planned expansion into myelodysplastic syndromes (MDS) and myelofibrosis (MF). With more than seven d
84dPR
CERo Therapeutics Provides Shareholder Update
Ongoing activities, including new engagement to relist on Nasdaq, new board member, continued advancement of Phase 1 trial into MDS patients, strategic engagement, and continued support from lead investor, underscore the Company's operational momentum SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, provides an update through the letter to stockholders and stakeholders from CEO Chris Ehrlich: To our stockholders and stakeholders: Following our recent Form 8-K filing confirming receipt of convertible deb
102dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
106dPR
CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25
109dSEC
CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Changes in Registrant's Certifying Accountant, Leadership Update
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
119dSEC
SEC Form 424B3 filed by CERo Therapeutics Holdings Inc.
424B3 - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
119dSEC
CERo Therapeutics Holdings Inc. filed SEC Form 8-K: Other Events
8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)
119dPR
CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient
Poster to be presented at Tandem Meeting of the American Society of Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) on February 5, 2026 SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanisms, announces a presentation highlighting data to date from the Company's Phase 1 clinical trial, called CERTAIN-T, of its lead compound, CER-1236. Reflective of the Company's recent clinical update, the data highlight results from the first cohort

CERO FAQ

6 questions

Where does CERO stock trade?
CERo Therapeutics Holdings Inc. (CERO) is listed on NASDAQ.
What sector and industry is CERO in?
CERo Therapeutics Holdings Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
When did CERo Therapeutics Holdings Inc. go public?
CERo Therapeutics Holdings Inc. (CERO) completed its IPO in 2021.
What are analysts saying about CERO?
CERo Therapeutics Holdings Inc. has had 1 recent analyst action on file. The most recent action was from D. Boral Capital: Buy with a $3000.00 price target on 2025-06-23. Recent price targets cluster around $3000.00.
What companies are similar to CERO?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CERO side-by-side with any of them on Quantisnow.
How can I track CERO on Quantisnow?
Quantisnow aggregates CERo Therapeutics Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CERO to receive live email and push alerts on every new disclosure.